Clinical trial
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or…
NCT00387751 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00387751 |
|---|---|
| Title | Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma |
| Official title | A Phase II, Pharmacokinetic (PK), Pharmacodynamic (PD) and Biological Correlative Study of the Efficacy and Safety of Dual Antiangiogenic Inhibition Using Bevacizumab and Sorafenib in Patients With Advanced Malignant Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma |
| Intervention type | Biological, Drug, Other |
| Interventions | Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate |
| Enrollment | 14 |
| Start date | Aug 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Jan 1, 2010 |
| First posted | Oct 13, 2006 |
| Last update posted | Nov 22, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: